Recent results confirmed the robustness of Aivlosin® sales and ECO’s business model, against a challenging market backdrop in China and the US. Although we have tempered short-term estimates to reflect the uncertain timing of China recovery, we believe ECO is well placed to benefit from expected industry changes. We continue to view ECO as a core holding in Animal Health, and reiterate our positive stance.
17 Jul 2019
China recovery supports medium-term outlook
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
China recovery supports medium-term outlook
ECO Animal Health Group plc (EAH:LON) | 94.0 0 0.0% | Mkt Cap: 63.7m
- Published:
17 Jul 2019 -
Author:
Jens Lindqvist -
Pages:
3
Recent results confirmed the robustness of Aivlosin® sales and ECO’s business model, against a challenging market backdrop in China and the US. Although we have tempered short-term estimates to reflect the uncertain timing of China recovery, we believe ECO is well placed to benefit from expected industry changes. We continue to view ECO as a core holding in Animal Health, and reiterate our positive stance.